Literature DB >> 20451965

Use of tumor necrosis factor-alpha-coated gold nanoparticles to enhance radiofrequency ablation in a translational model of renal tumors.

Renato Nardi Pedro1, Thishore Thekke-Adiyat, Raghav Goel, Mithun Shenoi, Joel Slaton, Steve Schmechel, John Bischof, James Kyle Anderson.   

Abstract

OBJECTIVES: Radiofrequency ablation (RFA) has been most effective when the tumors are small, exophytic, and away from vital structures. We enlarged the size of the ablation kill zone by infusing a 30-nm tumor necrosis factor-alpha and polyethylene glycol-coated gold nanoparticle (CYT-6091, CytImmune Sciences, Inc.) before ablation in a rabbit kidney tumor model.
MATERIALS AND METHODS: A total of 37 New Zealand White rabbits had VX-2 tumors implanted into their bilateral kidneys; they were then split into 3 treatment groups of 10 rabbits each and a sham group of 7 rabbits as follows: (1) CYT-6091 only, (2) RFA only, (3) CYT-6091 followed 4 hours later by RFA. Gross and microscopic measurements of the ablation size as well as histologic analysis using hematoxylin and eosin staining were performed to determine the effect of CYT-6091 on the ablation.
RESULTS: The RFA + CYT-6091 group had a larger zone of complete cell death than the RFA-only group when measured on microscopic examination (0.30 +/- 0.07 vs 0.23 +/- 0.03 mL, P = .03). The zone of partially ablated tissue was smaller in the RFA + CYT-6091 group than in the RFA-only group (0.08 +/- 0.02 vs 0.13 +/- 0.05 mL, P = .01).
CONCLUSIONS: We have demonstrated the efficacy of CYT-6091 in enhancing RFA in a translational kidney tumor model. The potential usage of CYT-6091 to improve RFA of renal cell carcinoma merits further study. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20451965     DOI: 10.1016/j.urology.2010.01.085

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  8 in total

1.  Nanotechnology for energy-based cancer therapies.

Authors:  Kyle Gilstrap; Xiaoxiao Hu; Xiongbin Lu; Xiaoming He
Journal:  Am J Cancer Res       Date:  2011-03-11       Impact factor: 6.166

Review 2.  Applications of nanoparticles in the detection and treatment of kidney diseases.

Authors:  Chris Brede; Vinod Labhasetwar
Journal:  Adv Chronic Kidney Dis       Date:  2013-11       Impact factor: 3.620

3.  Gold nanoprobes for theranostics.

Authors:  Balaji Panchapakesan; Brittany Book-Newell; Palaniappan Sethu; Madhusudhana Rao; Joseph Irudayaraj
Journal:  Nanomedicine (Lond)       Date:  2011-12       Impact factor: 5.307

4.  Nanoparticle preconditioning for enhanced thermal therapies in cancer.

Authors:  Mithun M Shenoi; Neha B Shah; Robert J Griffin; Gregory M Vercellotti; John C Bischof
Journal:  Nanomedicine (Lond)       Date:  2011-04       Impact factor: 5.307

5.  Fiber-Optic Distributed Sensing Network for Thermal Mapping of Gold Nanoparticles-Mediated Radiofrequency Ablation.

Authors:  Akbota Sametova; Sabit Kurmashev; Zhannat Ashikbayeva; Aida Amantayeva; Wilfried Blanc; Timur Sh Atabaev; Daniele Tosi
Journal:  Biosensors (Basel)       Date:  2022-05-18

6.  Development of multigene expression signature maps at the protein level from digitized immunohistochemistry slides.

Authors:  Gregory J Metzger; Stephen C Dankbar; Jonathan Henriksen; Anthony E Rizzardi; Nikolaus K Rosener; Stephen C Schmechel
Journal:  PLoS One       Date:  2012-03-15       Impact factor: 3.240

Review 7.  Interaction of gold nanoparticles with proteins and cells.

Authors:  Pengyang Wang; Xin Wang; Liming Wang; Xiaoyang Hou; Wei Liu; Chunying Chen
Journal:  Sci Technol Adv Mater       Date:  2015-06-18       Impact factor: 8.090

8.  Percutaneous ultrasound guided PEG-coated gold nanoparticles enhanced radiofrequency ablation in liver.

Authors:  Tudor Mocan; Rares Stiufiuc; Calin Popa; Iuliana Nenu; Cosmin Pestean; Andras Laszlo Nagy; Lavinia Patricia Mocan; Daniel Corneliu Leucuta; Nadim Al Hajjar; Zeno Sparchez
Journal:  Sci Rep       Date:  2021-01-14       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.